Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Inhibikase Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -39.55%, a change of 12.30% year-over-year.
Inhibikase Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -30.40%, a change of 12.23% year-over-year.
Inhibikase Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -27.91%, a change of 1.10% year-over-year.
Inhibikase Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -65.37%, a 101.77% decline year-over-year.
Inhibikase Therapeutics, Inc. roe for fiscal 2025 was -27.91%, a change of 1.10% from fiscal 2024.
Inhibikase Therapeutics, Inc. roe for fiscal 2024 was -29.01%, a change of 144.33% from fiscal 2023.
Inhibikase Therapeutics, Inc. roe for fiscal 2023 was -173.34%, a change of -87.51% from fiscal 2022.
Inhibikase Therapeutics, Inc. roe for fiscal 2022 was -85.83%, a change of -47.34% from fiscal 2021.